Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:fulvestrant
|
| gptkbp:activities |
m TOR inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:legislation
gptkb:2009 gptkb:United_States |
| gptkbp:brand |
Afinitor
Zortress |
| gptkbp:class |
macrolide
|
| gptkbp:developed_by |
gptkb:Novartis
|
| https://www.w3.org/2000/01/rdf-schema#label |
everolimus
|
| gptkbp:ingredients |
C53 H83 N17 O14
|
| gptkbp:is_atype_of |
L01 X E10
|
| gptkbp:is_used_for |
treatment of cancer
treatment of organ transplant rejection treatment of tuberous sclerosis complex |
| gptkbp:manager |
oral
intravenous |
| gptkbp:related_to |
rapamycin
|
| gptkbp:side_effect |
fatigue
nausea diarrhea increased risk of infection liver problems mouth sores high blood sugar |
| gptkbp:type_of |
159351-69-6
|